Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
cyclin-dependent kinase inhibitor |
| gptkbp:ATCCode |
none
|
| gptkbp:CASNumber |
gptkb:186692-46-6
|
| gptkbp:category |
investigational drug
purine analog |
| gptkbp:chemicalFormula |
C19H26N6O
|
| gptkbp:clinicalTrialPhase |
Phase II
|
| gptkbp:developedBy |
gptkb:cancer
neurodegenerative diseases |
| gptkbp:discoveredBy |
gptkb:Pierre_Fabre_Laboratories
|
| gptkbp:hasInChIKey |
QXJYYZQXAFYFJA-IBGZPJMESA-N
|
| gptkbp:hasSMILES |
CC(C)N1C=NC2=C1N=CN2C(Cc3ccccc3)NCC(C)O
|
| https://www.w3.org/2000/01/rdf-schema#label |
roscovitine
|
| gptkbp:IUPACName |
gptkb:(R)-2-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine
|
| gptkbp:mechanismOfAction |
inhibits cyclin-dependent kinases (CDKs)
|
| gptkbp:molecularWeight |
354.45 g/mol
|
| gptkbp:otherName |
gptkb:CYC202
gptkb:Seliciclib |
| gptkbp:PubChem_CID |
gptkb:CHEMBL297
160355 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:target |
gptkb:CDK7
gptkb:CDK9 gptkb:CDK2 |
| gptkbp:bfsParent |
gptkb:cdc2
|
| gptkbp:bfsLayer |
5
|